Antihyperglycaemic treatment patterns, observed glycaemic control and determinants of treatment change among patients with type 2 diabetes in the United Kingdom primary care: a retrospective cohort study

BMC Endocrine Disorders

Javier Cid Ruzafa²  Beth D Mitchell³  Andrew Maguire¹ 

[1] Director Epidemiology and Database Analyses, OXON Epidemiology Ltd., The Euston Office, 1 Euston Square, 40 Melton Street, London NW1 2FD, UK;Research Scientist & Epidemiologist, Health Economics & Epidemiology, Evidera, Metro Building, 6th Floor, 1 Butterwick, London W6 8DL, UK;Research Scientist, Global Patient Safety, Eli Lilly and Company, Indianapolis IN 46285, USA

关键词: Cohort;    Population based;    Treatment patterns;    Non-insulin antihyperglycaemic therapy;    Oral antidiabetics;    Type 2 diabetes mellitus;   

Others  :  1085028
DOI  :  10.1186/1472-6823-14-73

 received in 2014-05-07, accepted in 2014-08-19,  发布年份 2014

【 摘 要 】

Background

The initial treatment strategy for patients with type 2 diabetes includes lifestyle change recommendations. When patients are not successful in controlling their blood glucose levels through healthier lifestyle pharmaceutical agents are recommended. The objective of this study is to identify determinants of initial treatment change following initiation of non-insulin antihyperglycaemic treatment (OAD) for UK patients with type 2 diabetes.

Methods

A retrospective cohort study using primary care data from the Clinical Practice Research Datalink between January 2006 and February 2011. Each patient had an OAD prescription. The main treatment pattern outcomes were discontinuation, switching, augmentation and initiation of insulin. Glycaemic control was assessed using HbA1c.

Results

63,060 patients initiated OAD therapy 2006–2010 and 3.4% were prescribed insulin during follow-up. 26% with at least four years of follow-up remained on the initial treatment. Metformin dominated (90%) in UK primary care. Around 75% had a record of HbA1c testing prior to initiating therapy. On initiating OAD, half the patients had HbA1c values >65 mmol/mol and one quarter >80 mmol/mol. The initial values of HbA1c were reduced after 12 months and remained stable. There were 15%-18% of patients whose values increased since initiating OAD. Increased baseline HbA1c is associated with increased chance of augmentation and decreased chance of discontinuation. HbA1c values at 1 year were associated with a three-fold increase in the chance of augmentation, 130% increase in the chance of switching and 14% increase in the chance of discontinuation with each 10 mmol/mol increase. Following initiation of OAD, HbA1c was reduced by an average of 16 mmol/mol during the first year.

Conclusion

There are patients for whom glycaemic control worsens and a majority remained above the recommended level, suggesting an unmet need despite the availability of many OAD.

【 授权许可】

   
2014 Maguire et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Gonzalez EL, Johansson S, Wallander MA, Rodriguez LA: Trends in the prevalence and incidence of diabetes in the UK: 1996–2005. J Epidemiol Community Health 2009, 63(4):332-336.
• [2]Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J: Harrison's Principles of Internal Medicine. 17th edition. New York: McGraw-Hill Medical Publishing Division; 2008.
• [3]Ismail-Beigi F: Clinical practice: glycemic management of type 2 diabetes mellitus. N Engl J Med 2012, 366(14):1319-1327.
• [4]National Collaborating Centre for Chronic Conditions: Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London: Royal College of Physicians; 2008.
• [5]Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes http://www.nice.org.uk/CG87ShortGuideline webcite
• [6]Oglesby AK, Secnik K, Barron J, Al-Zakwani I, Lage MJ: The association between diabetes related medical costs and glycemic control: a retrospective analysis. Cost Eff Resour Alloc 2006, 4:1. BioMed Central Full Text
• [7]Chen SY, Siu K, Kovacs B, Stokes M, Rao P, Sander S, Boulanger L: Clinical and economic outcomes associated with National Kidney Foundation guideline-concordant oral antidiabetic drug treatment among type 2 diabetes patients with chronic kidney disease. Curr Med Res Opin 2012, 28(4):493-501.
• [8]Fowler JM: Diabetes treatment: oral agents. Clin Diabetes 2010, 28(3):132-136.
• [9]McEwan P, Evans M, Bergenheim K: A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab 2010, 12(7):623-630.
• [10]Cai B, Xu W, Bortnichak E, Watson DJ: An algorithm to identify medical practices common to both the General Practice Research Database and The Health Improvement Network database. Pharmacoepidemiol Drug Saf 2012, 21(7):770-774.
• [11]Chisholm J: The read clinical classification. BMJ 1990, 300(6732):1092.
• [12]Willey CJ, Andrade SE, Cohen J, Fuller JC, Gurwitz JH: Polypharmacy with oral antidiabetic agents: an indicator of poor glycemic control. Am J Manag Care 2006, 12(8):435-440.
• [13]Czernichow S, Zoungas S, Chalmers J, Patel A, Marre M, Colagiuri S, Hamet P, Li Q, Billot L: Patterns of use of glucose lowering treatments at baseline and during follow-up in ADVANCE. Diabetologia 2010, 53(Suppl 1):S363.
• [14]Plat A, Penning-van Beest F, Kessabi S, Groot M, Herings R: Change of initial oral antidiabetic therapy in type 2 diabetic patients. Pharm World Sci 2009, 31(6):622-626.
• [15]Lamberts EJ, Nijpels G, Welschen LM, Hugtenburg JG, Dekker JM, Souverein PC, Bouvy ML: Long term patterns of use after initiation of oral antidiabetic drug therapy. Pharmacoepidemiol Drug Saf 2011, 20(4):351-358.
• [16]Jermendy G, Wittmann I, Nagy L, Kiss Z, Rokszin G, Abonyi-Toth Z, Katona L, Paragh G, Karadi I, Merkely B: Persistence of initial oral antidiabetic treatment in patients with type 2 diabetes mellitus. Med Sci Monit 2012, 18(2):CR72-CR77.
• [17]Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA: Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes. Diabetes Obes Metab 2008, 10(8):638-645.
• [18]Haynes K, Bilker WB, Tenhave TR, Strom BL, Lewis JD: Temporal and within practice variability in the health improvement network. Pharmacoepidemiol Drug Saf 2011, 20(9):948-955.
• [19]Walker AM: Matching on provider is risky. J Clin Epidemiol 2013, 66(8 Suppl):S65-S68.